Legacy Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-14,252
Closed -$1.23M 455
2024
Q4
$1.23M Buy
14,252
+5,507
+63% +$596K 0.12% 136
2024
Q3
$1.04M Buy
8,745
+839
+11% +$112K 0.11% 142
2024
Q2
$1.13M Buy
7,906
+1,760
+29% +$233K 0.14% 119
2024
Q1
$789K Buy
+6,146
New +$732K 0.1% 162

Other funds holding NVO

Legacy Advisors's NVO Position: Q1 2025 in Review

Legacy Advisors sold out of Novo Nordisk (NVO) in Q1 2025, closing a stake of 14,252 shares — an estimated $1.23M sold.

Legacy Advisors first reported a position in NVO in Q1 2024 and held it in 4 quarters. The position peaked at $1.23M in Q4 2024. 1,528 funds tracked by Wall St. Rank hold NVO as of Q1 2025.

  • Legacy Advisors reported no remaining Novo Nordisk position as of Q1 2025 after selling out during the quarter.
  • Legacy Advisors sold 14,252 Novo Nordisk shares in Q1 2025, an estimated $1.23M.
  • Legacy Advisors first reported a position in Novo Nordisk in Q1 2024 and held it in 4 quarters.
  • Legacy Advisors's Novo Nordisk position peaked at $1.23M in Q4 2024.
  • 1,528 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2025.

Based on Legacy Advisors's 13F filing for Q1 2025, filed 23 Apr 2025.